Effectiveness of Chinese herbal medicine as a complementary treatment for neutropenia prevention and immunity modulation during chemotherapy in patients with breast cancer: a real-world pragmatic clinical trial
Early Phase 1
Recruiting
- Conditions
- Breast cancer
- Registration Number
- ITMCTR2023000054
- Lead Sponsor
- ational Research Institute of Chinese Medicine, Ministry of Health and Welfare, Taiwan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
Patients aged more than 20 years, with a histologically confirmed diagnosis of breast cancer before the initiation of chemotherapy, are considered eligible for this study.
Exclusion Criteria
Patients who will not be able to finish the chemotherapy and follow-up procedures, those who receive other medication, and those with an Eastern Cooperative Oncology Group (ECOG) score of 3–4 will be excluded from the study.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method